Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

By Ian G. McKeith, T. Ser, P. Spano, M. Emre, K. Wesnes, R. Anand, A. Cicin‐Sain, R. Ferrara, R. Spiegel. The Lancet, 2000

1,128 citations recorded by the source corpus.

Subfields: Neurology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/6147b06055ea2809bd6513e8c41827a0b7aa6580

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Ian G. McKeith

In Pharmacology

1. Ian G. McKeith

In Psychiatry and Mental health

1. Ian G. McKeith

Citations in the corpus

• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop (2006, positive): “The imaging studies have shown possibilities to improve case detection and open label studies have demonstrated the effectiveness of all three generally available CHEIs in DLB and PDD. Placebo controlledtrial data is only available to date for rivastigmine [56,57].”
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline (2008, background): “One trial (52) evaluated dementia associated with Parkinson disease, 1 study (54) evaluated Lewy body dementia, and the remainder evaluated Alzheimer disease.”